Autonomix Medical, Inc. (NASDAQ: AMIX) experienced a significant premarket surge on Wednesday, climbing 54.5% to $4.25 after closing at $2.75 the previous session. The move came after a Tuesday SEC filing highlighted a notable disparity between the company's cash holdings and its market valuation.
According to the filing, Autonomix held $5.1 million in cash with 971,043 shares outstanding, translating to approximately $5.25 in gross cash per share. This figure stood 91% above Tuesday's closing price of $2.75, creating a valuation gap that traders moved to exploit. However, even after the premarket rally, shares remained roughly 19% below the gross cash per share level, indicating persistent discount.
The filing also revealed a substantial warrant overhang. Newly issued Series D warrants represent 88.3% of the existing share count, or 857,462 additional shares. The warrants carry a strike price of $5.75 and a term of 5.5 years. With shares trading around $4.25, the warrants are out of the money, making immediate exercise unlikely. However, their existence creates potential dilution that could cap upside.
Autonomix's cash position has been declining. As of March 31, the company reported $7 million in cash. A warrant exercise in July generated roughly $2.6 million gross, but by July 28, cash had fallen to $5.1 million. This implies net cash usage of about $4.5 million over 119 days, or roughly $1.1 million per month. Based on fiscal 2026 operating cash use of $12.3 million, the current cash provides approximately five months of runway, excluding any future financing or warrant exercises.
If all Series D warrants were exercised at $5.75, Autonomix would receive about $4.9 million in additional cash, boosting total cash to roughly $10 million. Shares outstanding would rise to 1,828,505, and gross cash per share would increase to about $5.49. The runway would extend to about 9.8 months at the current burn rate. However, the company noted that warrant exercises are not guaranteed.
The S-3 filing is not a new primary offering but covers the resale of shares tied to the Series D warrants. Autonomix only receives cash when warrants are exercised, not from subsequent resales. The stock count has already grown 79% since June's reverse split due to the July exercise of 428,731 existing warrants.
Market activity has been intense. On Tuesday, 10.6 million shares changed hands, 26.8 times the 65-day average. Despite the surge, AMIX was still down 30.9% over the prior five sessions. The stock's volatility reflects the tension between cash value and dilution risk.
From an operational standpoint, Autonomix remains in early development. On July 24, the company reported an animal study showing renal neural signals before and after targeted ablation, which CEO Brad Hauser called a critical milestone. However, the platform is still investigational, and enrollment in an expansion study was halted due to inconsistent early clinical results. Management estimates that an additional $25 million to $32 million will be needed before the first commercial launch.
Risks remain elevated. The cash-per-share calculation does not account for liabilities or anticipated expenditures. Autonomix has no approved products, generates no revenue, and carries a going-concern notice. The stock could be impacted by warrant exercises, clinical setbacks, or future funding rounds. This week's regular-session trading will determine whether the premarket gains hold, as the narrow range between cash value ($5.25) and warrant strike ($5.75) leaves little room for error.
